These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27305069)

  • 21. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.
    James RS; Sharp WS; Bastain TM; Lee PP; Walter JM; Czarnolewski M; Castellanos FX
    J Am Acad Child Adolesc Psychiatry; 2001 Nov; 40(11):1268-76. PubMed ID: 11699800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy.
    Mohammadi M; Akhondzadeh S
    Acta Med Iran; 2011; 49(8):487-98. PubMed ID: 22009816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.
    McGough JJ; Biederman J; Wigal SB; Lopez FA; McCracken JT; Spencer T; Zhang Y; Tulloch SJ
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):530-8. PubMed ID: 15908835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines.
    National Toxicology Program
    NTP CERHR MON; 2005 Jul; (16):vii-III1. PubMed ID: 16130031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
    Daughton JM; Kratochvil CJ
    J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):240-248. PubMed ID: 19242289
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacotherapy of adult ADHD.
    Dodson WW
    J Clin Psychol; 2005 May; 61(5):589-606. PubMed ID: 15723384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effectiveness of stimulants of retard forms in children and adolescents with ADHD--a systematic overview].
    Sevecke K; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2004 Nov; 32(4):265-78. PubMed ID: 15565896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
    Konstenius M; Jayaram-Lindström N; Beck O; Franck J
    Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder.
    Weisler RH
    Expert Opin Pharmacother; 2007 Apr; 8(6):745-58. PubMed ID: 17425471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
    Gerlach M; Grünblatt E; Lange KW
    Atten Defic Hyperact Disord; 2013 Jun; 5(2):71-81. PubMed ID: 23605387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimulant dosing for children with ADHD: a medical claims analysis.
    Olfson M; Marcus S; Wan G
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):51-9. PubMed ID: 19218896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First Amphetamine Transdermal Patch Approved for ADHD.
    Larkin HD
    JAMA; 2022 May; 327(17):1642. PubMed ID: 35503364
    [No Abstract]   [Full Text] [Related]  

  • 35. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulant therapy in the management of ADHD: mixed amphetamine salts (extended release).
    Faraone SV
    Expert Opin Pharmacother; 2007 Sep; 8(13):2127-34. PubMed ID: 17714065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs for ADHD.
    Med Lett Drugs Ther; 2015 Mar; 57(1464):37-40. PubMed ID: 25758544
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL; Kuchibhatla A
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Attention-deficit/hyperactivity disorder. Clinical and treatment aspects].
    Diaconu G; Grigore I; Burlea M
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(3):656-62. PubMed ID: 20191811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.